Metabolic HealthResearch PaperOpen Access

CVOT Summit 2025 reveals first head-to-head tirzepatide heart trial and new combination therapies

The 2025 CVOT Summit report reviews SURPASS-CVOT, oral orforglipron, finerenone plus empagliflozin, and baxdrostat across cardiovascular-kidney-metabolic disease.

Saturday, November 21, 2026 1 view
Published in Cardiovasc Diabetol
a doctor's hands holding a tirzepatide weekly injection pen beside a blood pressure cuff on a clinic desk

Summary

This report summarizes the 11th Cardiovascular Outcome Trial Summit, held virtually in November 2025. It reviews major 2025 trials across the cardiovascular-kidney-metabolic (CKM) disease continuum. - **SURPASS-CVOT** (13,165 adults with type 2 diabetes): tirzepatide was non-inferior to dulaglutide for major heart events (HR 0.92) but did not prove superior. All-cause death was lower (8.6% vs 10.2%), but that comparison was not multiplicity-adjusted. - **SURMOUNT-5** (750 adults): tirzepatide produced more weight loss than semaglutide (20.2% vs 13.7%). - **ATTAIN-1** (3,127 adults): the oral GLP-1 drug orforglipron cut weight by up to 11.2% at 72 weeks, vs 2.1% on placebo. Discontinuations for side effects rose with dose. - **Other trials**: the report also covers finerenone plus empagliflozin (CONFIDENCE), the aldosterone synthase inhibitor baxdrostat (BaxHTN) and vericiguat (VICTOR). Their results fall in the part of the text that was not supplied. This is an expert narrative report of published trials, not a new study.

Detailed Summary

Heart, kidney and metabolic diseases are tightly linked, and the American Heart Association named the overlap cardiovascular-kidney-metabolic (CKM) syndrome in 2023. The CVOT Summit report reviews 2025 trials that shape how this syndrome is treated. This matters for healthspan because these conditions drive much age-related disability and death. The report is a narrative expert summary of published trials, not a new analysis. The supplied text cuts off partway through the incretin section, during the ATTAIN-1 table.

SURPASS-CVOT was the first head-to-head cardiovascular outcome trial. It randomized 13,165 adults with type 2 diabetes to tirzepatide, a dual GIP/GLP-1 receptor agonist, or dulaglutide, a GLP-1 receptor agonist. - **Primary composite** (cardiovascular death, heart attack or stroke): 12.2% vs 13.1% (HR 0.92; 95% CI 0.83 to 1.01). Non-inferiority was met (P=0.003); superiority was not (P=0.09). - **All-cause death**: 8.6% vs 10.2% (HR 0.84; 0.75 to 0.94). This was a key secondary endpoint with confidence intervals not adjusted for multiplicity, so it is hypothesis-generating. - **Comparator**: dulaglutide belongs to a drug class with demonstrated cardioprotection, which may have narrowed the gap.

On function and metabolic markers, tirzepatide outperformed dulaglutide on several measures: - **Kidney function**: in participants with high or very-high-risk kidney disease (about 2,900), eGFR fell less (-5.72 vs -8.90 mL/min/1.73m2 at 36 months). - **Triglycerides**: fell more (-24.2% vs -10.2% at 24 months). - **Systolic pressure**: fell more (-6.2 vs -4.1 mmHg).

Harms were not trivial. Treatment discontinuation for adverse events was 13.2% vs 10.1%, gastrointestinal events 42.5% vs 35.9%, and acute kidney injury 3.4% vs 2.7%. Serious adverse events were similar.

On weight, two trials stood out: - **SURMOUNT-5** (750 adults): tirzepatide cut weight 20.2% vs 13.7% with semaglutide (difference -6.5 points; P<0.001). Waist reduction was 18.4 vs 13.0 cm. - **ATTAIN-1**: tested once-daily oral orforglipron in 3,127 adults (2,178 on active drug, 949 on placebo). At 72 weeks, weight fell 7.5%, 8.4% and 11.2% at 6, 12 and 36 mg, vs 2.1% on placebo. Discontinuation for adverse events rose with dose, reaching 10.3% at 36 mg vs 2.7% on placebo, mostly from gastrointestinal effects.

The report also highlights several trials whose results are not in the supplied text: - **CONFIDENCE**: combination therapy with finerenone (a nonsteroidal mineralocorticoid receptor antagonist) plus empagliflozin (an SGLT2 inhibitor), compared with either drug alone. - **MIRO-CKD**: balcinrenone plus dapagliflozin. - **BaxHTN**: the aldosterone synthase inhibitor baxdrostat vs placebo. - **VICTOR**: the soluble guanylate cyclase stimulator vericiguat vs placebo.

These approaches target hormonal and signaling pathways beyond glucose control. That is the 'growing evidence base for combination therapies' the report emphasizes. Their effect sizes and safety data, including potassium effects, could not be verified here.

Overall, the report points toward layered, mechanism-based treatment of CKM disease. Caveats: - The trials are summarized by summit faculty. - Many secondary results are not multiplicity-controlled. - The kidney and metabolic findings shown are markers rather than hard outcomes. - Trial sponsorship is not stated in the supplied text.

The tables show real harms alongside the benefits.

Key Findings

  • SURPASS-CVOT (n=13,165): MACE-3 12.2% tirzepatide vs 13.1% dulaglutide, HR 0.92 (0.83-1.01); non-inferior (P=0.003), superiority not shown (P=0.09)
  • All-cause mortality was lower with tirzepatide: 8.6% vs 10.2%, HR 0.84 (0.75-0.94); key secondary endpoint, not multiplicity-adjusted, so hypothesis-generating
  • SURPASS-CVOT harms: discontinuation for adverse events 13.2% vs 10.1%, gastrointestinal events 42.5% vs 35.9%, acute kidney injury 3.4% vs 2.7%
  • SURMOUNT-5 (n=750): weight loss 20.2% tirzepatide vs 13.7% semaglutide, difference -6.5 points (P<0.001)
  • ATTAIN-1 oral orforglipron (n=3,127): weight change -7.5%, -8.4%, -11.2% by dose vs -2.1% placebo at 72 weeks; discontinuation for adverse events up to 10.3% vs 2.7%
  • Also reviewed, with results outside the supplied text: CONFIDENCE (finerenone + empagliflozin vs monotherapy), BaxHTN (baxdrostat vs placebo), VICTOR (vericiguat vs placebo)

Methodology

This is a narrative conference report summarizing published randomized trials, not a systematic review or new analysis. Statistical details are as reported by the original trials. Primary endpoints used multiplicity-controlled testing, and many secondary confidence intervals were unadjusted. The supplied text gives sizes for three trials: SURPASS-CVOT (13,165), ATTAIN-1 (3,127) and SURMOUNT-5 (750). The text ends partway through the incretin section, so later trials and topics are not covered here.

Study Limitations

The report is an expert narrative review, so selection of trials and interpretation may reflect the faculty's views, and the summit organizers may have industry ties not stated in the supplied text. Many secondary and kidney findings are surrogate or not multiplicity-adjusted. The supplied text is truncated, so the conclusions, remaining trials and policy sections were not assessed.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: